Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome.
OBJECTIVE
To determine the concomitant incidence, molecular diversity, management and outcome of nosocomial candidemia and candiduria in intensive care unit (ICU) patients in France.


METHODS
A 1-year prospective observational study in 24 adult ICUs.


METHODS
Two hundred and sixty-two patients with nosocomial candidemia and/or candiduria.


RESULTS
Blood and urine samples were collected when signs of sepsis were present. Antifungal susceptibility of Candida strains was determined; in addition, all blood and 72% of urine C. albicans isolates were analyzed by using multi-locus sequence type (MLST). The mean incidences of candidemia and candiduria were 6.7 and 27.4/1000 admissions, respectively. Eight percent of candiduric patients developed candidemia with the same species. The mean interval between ICU admission and candidemia was 19.0 +/- 2.9 days, and 17.2 +/- 1.1 days for candiduria. C. albicans and C. glabrata were isolated in 54.2% and 17% of blood and 66.5% and 21.6% of urine Candida-positive cultures, respectively. Fluconazole was the most frequently prescribed agent. In all candidemic patients, the prescribed curative antifungal agent was active in vitro against the responsible identified strain. Crude ICU mortality was 61.8% for candidemic and 31.3% for candiduric patients. Seventy-five percent of the patients were infected with a unique C. albicans strain; cross-transmission between seven patients was suggested in one hospital.


CONCLUSIONS
Candidemia is late-onset ICU-acquired infection associated with high mortality. No difference in susceptibility and genetic background were found between blood and urine strains of Candida species.
Bougnoux
Marie-Elisabeth
ME
Hôpital Necker-Enfants Malades, Service de Bactériologie, Virologie, Parasitologie et Hygiène, 149, rue de Sèvres, 75473 Paris Cedex 15, France. marie-elisabeth.bougnoux@nck.aphp.fr
Kac
Guillaume
G
Aegerter
Philippe
P
d'Enfert
Christophe
C
Fagon
Jean-Yves
JY
D018806:APACHE; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D002175:Candida / Q000145:classification / Q000302:isolation & purification; D002177:Candidiasis / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology* / Q000652:urine; D016009:Chi-Square Distribution; D016638:Critical Illness; D003428:Cross Infection / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology* / Q000652:urine; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007362:Intensive Care Units; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D011446:Prospective Studies; D012307:Risk Factors
D000935:Antifungal Agents